Endogenous CD8 T cells found to drive lymphoma response to CAR-T therapy
Start here
A bioRxiv preprint posted October 27, 2026 reports that durable efficacy of CD19 CAR-T therapy in large B-cell lymphoma depends on cooperation between CAR-T cells and endogenous CD8+ T cells to eliminate malignant cells. The study integrates whole-genome and transcriptome data from 54 relapsed or refractory patients with functional assays and mathematical modeling. Tumors carrying biallelic loss of MHC-I or CD58 showed higher genomic complexity and neoantigen burden and were resistant to CAR-T therapy, suggesting tumor immune-evasion mechanisms outside the CD19 axis shape outcomes. The work has appeared as a preprint and has not yet undergone peer review or journal publication.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biorxiv.orgPickLymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells
Durable efficacy of CD19 CAR-T therapy in large B-cell lymphoma depends on CAR-T cells cooperating with endogenous CD8+ T cells (eCD8) to eliminate malignant cells. The bioRxiv preprint integrates whole-genome and transcriptome data from 54 relapsed or refractory patients with functional assays and mathematical modeling; tumors with biallelic loss of MHC-I or CD58 showed higher genomic complexity and neoantigen burden and were resistant to CAR-T therapy.
Heat trend for this story
Heat now 5·Peak in the comparable set 10 (Oct 27 08:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.